ConductScience.org, home

Paper9605801

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Lancet, 1998. Cited by 3,176 papers, by iCite.

Cite this record

ConductScience Library. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Papers, record 9605801. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9605801

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
PubMed
Journal
Lancet
PubMed
Year
1998
PubMed
Publication types
Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3,176
iCite
Relative citation ratio, by iCite
80.6
iCite
Revised in PubMed
2025-12-16
PubMed

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, HormonalMajor topic
Breast NeoplasmsMajor topic
TamoxifenMajor topic
Adult
Age Factors
Aged
Carrier Proteins
Chemotherapy, Adjuvant
Colorectal Neoplasms
Endometrial Neoplasms
Female
Humans
Incidence
Menopause
Middle Aged
Neoplasm Recurrence, Local
Receptors, Estrogen
Survival Rate
Time Factors

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00603967Effect of Aromatase Inhibitors on Bones and GenesBackgroundClinicalTrials.gov
NCT03917082Limited Adjuvant Endocrine Therapy for Low Risk Breast CancerBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections4

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in9717952Tamoxifen in early breast cancer.https://conductscience.org/library/papers/9717952PubMed
Comment in9717953Tamoxifen in early breast cancer.https://conductscience.org/library/papers/9717953PubMed
Comment in9717954Tamoxifen in early breast cancer.https://conductscience.org/library/papers/9717954PubMed
Comment in9717955Tamoxifen in early breast cancer.https://conductscience.org/library/papers/9717955PubMed

Download CSV of comments and corrections

Cited by867

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3,176 citations.

PMIDTitleJournalYearIn PapersSource
42980869Co-payments and adherence to endocrine therapy among Medicaid beneficiaries with breast cancer.Breast Cancer Res Treat2026https://conductscience.org/library/papers/42980869PubMed
42959345Disease-guided targeted protein degradation and clearance: matching strategies to pathological protein states.Front Med (Lausanne)2026https://conductscience.org/library/papers/42959345PubMed
42844328ESR1 mutations are associated with enhanced MTORC1 signaling in a context-dependent manner.Commun Biol2026https://conductscience.org/library/papers/42844328PubMed
42804883Performance of large language models in ambiguous treatment scenarios of early breast cancer.Breast2026https://conductscience.org/library/papers/42804883PubMed
42584460Tamoxifen Therapy Is Associated With Altered Intestinal P-Glycoprotein Activity In Vivo.J Clin Pharmacol2026https://conductscience.org/library/papers/42584460PubMed
42350394Prognostic consistency of oncotype DX® molecular assay across racial groups in early-stage hormone receptor-positive breast cancer.NPJ Breast Cancer2026https://conductscience.org/library/papers/42350394PubMed
42123574MicroRNA-Directed Biomarkers and Breast Cancer Therapeutics-Potential to Advance Personalised Approaches in Clinical Trials.Int J Mol Sci2026https://conductscience.org/library/papers/42123574PubMed
41939469Tamoxifen differentially modulates endometrial hyperplasia via wild-type and mutant p53 regulation of the ALKBH5-REG1A axis.Front Oncol2026https://conductscience.org/library/papers/41939469PubMed
41821351Recurrence Rate Following Breast Conservation Surgery: A Retrospective Cohort Study.Breast J2026https://conductscience.org/library/papers/41821351PubMed
41634433Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/41634433PubMed
41483282Interplay between AIB1 genotypes and radiotherapy in a Swedish population-based breast cancer cohort.Discov Oncol2026https://conductscience.org/library/papers/41483282PubMed
41474498Targeting estrogen receptor alpha in breast cancer for novel therapies resistance mechanisms and future directions.Discov Oncol2025https://conductscience.org/library/papers/41474498PubMed
41469392Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer.NPJ Breast Cancer2025https://conductscience.org/library/papers/41469392PubMed
41005350Racial Differences in Symptom Burden and Endocrine Therapy Adherence in Breast Cancer: A Post Hoc Analysis of a Randomized Trial.J Natl Compr Canc Netw2025https://conductscience.org/library/papers/41005350PubMed
40906937Cholesterol-Functionalized Porous PLA Microparticles for Enhanced Drug Delivery.ACS Appl Bio Mater2025https://conductscience.org/library/papers/40906937PubMed
40746386Leveraging values to promote adherence to endocrine therapy among breast cancer survivors: A mixed-methods investigation.J Contextual Behav Sci2022https://conductscience.org/library/papers/40746386PubMed
40600576CYP2D6 genotype and outcome in tamoxifen treated early breast cancer.Acta Oncol2025https://conductscience.org/library/papers/40600576PubMed
40571497Medicines and society: systemic change needed to address overprescribing.Br J Gen Pract2025https://conductscience.org/library/papers/40571497PubMed
40557948How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?Acta Oncol2025https://conductscience.org/library/papers/40557948PubMed
40490470Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention.NPJ Breast Cancer2025https://conductscience.org/library/papers/40490470PubMed

See all 867 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EREG2069PubTator's text mininghttps://conductscience.org/library/genes/2069

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Authors
  • Grants
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9605801

GET https://conductscience.org/api/papers/v1/9605801/cited_by?page=2